<div><p><b>Background:</p> </b><p>In the primary analysis (data cut-off: 27 August 2021) of the phase 3 HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) and demonstrated a durable long-term survival benefit versus sorafenib; durvalumab monotherapy was noninferior to sorafenib (Abou-Alfa et al. <em>NEJM Evid</em> 2022). Here, we report an updated 4-year OS analysis of HIMALAYA.</p>

<div><p><strong>Background</strong>: Genetic factors associated with DILI susceptibility have been observed to be largely drug specific. The aim of this study was to identify novel risk factors for Cholestatic-Mixed Drug Induced Liver Injury (CM-DILI).</p>

<div><p><b>Background:</p> </b><p>Due to a global shortage of liver grafts, transplant surgeons increasingly resort to transplanting DCD (donated after circulatory death) organs. However, these organs are more susceptible to complications as a result of increased ischemic reperfusion injury. The worst of which is primary non-function, requiring an urgent re-transplantation. To date, there is no reliable metric to estimate the amount of reperfusion injury prior to transplantation.

<div><p><b>Background: </b>Multiple metabolic and inflammatory pathways have been associated with patient outcome in biliary atresia (BA), however, the spatial relevance of these pathways among BA and non-BA disease controls has not been well defined. In the present study, we overcome this gap in knowledge and define the hepatic spatial transcriptome in pediatric cholestasis.</p>

<div><p><b>Background:</p> </b><p>Recurrence can occur in over 70% of hepatocellular carcinoma (HCC) patients within 5 years after curative resection. While histological microvascular invasion (MVI) predicts recurrence, it is ascertained from resected specimens and cannot provide pre-operative prognostication. We developed an artificial intelligence deep learning-based model using pre-operative computed tomography (CT) for predicting HCC recurrence.</p>

<div><p><b>Background:<span style="font-weight: 400;"> </b>Acute variceal bleed (AVB) from cardiofundal varices (GOV-2/IGV-1) is associated with high mortality rates in patients with liver cirrhosis. No consensus exists on the best modality to prevent rebleeding after an index episode of bleeding.</span></p>

<div><p><strong><b>Background:</strong> </b>Acute kidney injury (AKI) is a deadly complication of cirrhosis, and treatments are limited. Vasoconstrictors have been used to treat hepatorenal syndrome AKI (HRS-AKI), but the impact of augmenting mean arterial pressure (MAP) on all AKI types has not been studied, limiting the application of clinically-proven treatments for HRS-AKI to non-HRS-AKI. Herein, we precisely characterize the impact of MAP on AKI reversal, independent of subtype.</p>

<div><p><b>Background: </b>Patients with decompensated cirrhosis (DC) often experience high psychological symptom burden. Family caregivers of patients with DC are at risk for psychological distress.</p>

<div><p><b>Background:</p> </b><p>Non-alcoholic fatty liver disease (NAFLD) affects a substantial proportion of the general population, but little is known about the impact of specific nutrients on its prevention. Utilizing unbiased machine learning, we aimed to investigate the association between dietary nutrients and the development of NAFLD in the large UK Biobank dataset.</p>

<div><p><b>Background: </b>In the Phase 2b B-Clear study (209668), bepirovirsen (BPV; an antisense oligonucleotide) 300 mg for 24 weeks (wks) achieved sustained HBsAg and HBV DNA loss (&lt;lower limit of quantification [LLOQ] for 24 wks off BPV therapy) in 9% of participants (pts) who remained on nucleos[t]ide analogs (NA); end of BPV response rates were higher (26%), but some pts relapsed during follow-up. Response was higher in pts with lower baseline HBsAg (≤3000 vs ≤1000 IU/mL: 12% vs 16%).